Treace Medical Concepts (TMCI) Receivables (2020 - 2026)

Treace Medical Concepts has reported Receivables for 7 years, with the latest figure at $30.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 2.42% year-over-year to $30.4 million; the trailing twelve-month figure through Mar 2026 stood at $30.4 million (down 2.42% YoY), and the FY2025 full-year result was $42.2 million, up 3.31% from the prior year.
• Receivables for Q1 2026 stood at $30.4 million, down from $42.2 million in the prior quarter.
• The five-year high for Receivables was $42.2 million in Q4 2025, with the low at $16.0 million in Q1 2022.
• Historically, Receivables has averaged $28.4 million across 5 years, with a median of $29.2 million in 2022.
• Annual changes were most pronounced in 2023 — Receivables surged 65.03% — and 2024, when it fell 6.14%.
• Treace Medical Concepts' Receivables stood at $29.2 million in 2022, then surged by 30.5% to $38.1 million in 2023, then climbed by 7.09% to $40.8 million in 2024, then climbed by 3.31% to $42.2 million in 2025, then fell by 27.98% to $30.4 million in 2026.
• The last three Receivables figures came in at $30.4 million (Q1 2026), $42.2 million (Q4 2025), and $33.0 million (Q3 2025), per Business Quant data.